> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Xencor Picks Top Dose For Kidney Cancer Drug After 45.5% Response Rate In Small Cohort
- URL: https://www.bullished.co/xencor-picks-top-dose-for-kidney-cancer-drug-after-45-5-response-rate-in-small-cohort-28a12fc5/
- Published: 2026-10-26T11:55:50.000Z
- Updated: 2026-10-28T17:03:56.000Z
- Description: The company plans FDA talks on an accelerated approval path and a head-to-head trial against tivozanib, with cash it expects to last into 2029.
- Author: Matteo Parrino
- Tags: SEC Filings, XNCR, Industry: Healthcare

Xencor, a clinical-stage biotech that engineers antibody drugs for cancer and autoimmune disease, chose 400 mcg/kg as the [proposed Phase 3 dose](https://markets.ft.com/data/announce/detail?dockey=600-202610250435BIZWIRE%5FUSPRX%5F%5F%5F%5F20261025%5FBW921014-1&ref=bullished.co) of its kidney cancer drug XmAb819 after [45.5% of 11 evaluable patients](https://www.sec.gov/Archives/edgar/data/0001326732/000121390026112279/ea030959601ex99-2.htm?ref=bullished.co) at that dose had confirmed tumor responses. The company announced the results Sunday at the ESMO cancer congress in Madrid and filed them with the SEC in an [8-K](https://www.sec.gov/Archives/edgar/data/0001326732/000121390026112279/ea0309596-8k%5Fxencor.htm?ref=bullished.co) on Monday.

## The 400 mcg/kg numbers

As of an October 1, 2026 data cut, the 11 evaluable patients at [400 mcg/kg](https://markets.ft.com/data/announce/detail?dockey=600-202610250435BIZWIRE%5FUSPRX%5F%5F%5F%5F20261025%5FBW921014-1&ref=bullished.co) had five confirmed partial responses (45.5%) and one unconfirmed partial response, for an unconfirmed rate of 55%. Median progression-free survival, the time before the cancer worsens, had not been reached. More than 70% of patients remained on treatment, and the 6-month progression-free survival estimate was 82%.

The cohort is small: the 95% confidence interval on the 45.5% rate runs from 16.8% to 76.6%. Xencor said safety at this dose matched the lower-dose cohorts.

XmAb819 is a bispecific antibody that targets ENPP3 on tumor cells and recruits T cells to kill them. Patients in the study had all received a PD-(L)1 inhibitor and a VEGFR-targeted pill, with a median of three prior lines of therapy.

## Lower doses and safety

Of the 68 patients in the three expansion cohorts, response rates were measured in efficacy-evaluable subsets as of a September 1, 2026 data cut. The confirmed rate was 30% at 100 mcg/kg (30 patients) and 44% at 200 mcg/kg (25 patients).

Treatment was stopped over related adverse events in 5.9% of expansion patients, and 72.1% had a related event of Grade 3 or higher. The most common severe events were liver enzyme rises, rash and low blood pressure, mostly early in treatment, according to the company.

## Path to a late-stage trial

Xencor plans to discuss a potential accelerated approval pathway with the FDA in the first half of 2027, for patients who have exhausted standard care. In pooled data, patients who had progressed after a PD-(L)1 inhibitor and at least two VEGFR pills (n=42) had a 45% confirmed response rate. The triple-class group that also received a HIF2α inhibitor (n=23) had 35%. Xencor's presentation estimates about 9,200 US patients fit the first group in 2025, based on Komodo Health claims data.

The company also plans a global randomized trial against tivozanib, aiming to start a registration-enabling study by the end of 2027\. In a similar subgroup of another trial, tivozanib produced a 10.5% response rate and median progression-free survival of 5.4 months. Xencor cautions that cross-trial comparisons are illustrative only.

CEO Bassil Dahiyat said the company plans to start a potential registration-enabling study next year, and that cash runway into 2029 leaves it "well positioned" to push its oncology and autoimmune work.

Data from at least 20 patients at 400 mcg/kg and from subcutaneous dosing are due in the first half of 2027, alongside the end-of-Phase 1 meeting with the FDA.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Xencor Inc (XNCR)](https://www.sec.gov/Archives/edgar/data/0001326732/000121390026112279/ea0309596-8k%5Fxencor.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ea030959601ex99-1.htm — Xencor Inc 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001326732/000121390026112279/ea030959601ex99-1.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ea030959601ex99-2.htm — Xencor Inc 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001326732/000121390026112279/ea030959601ex99-2.htm?ref=bullished.co) — SEC EDGAR
- [Xencor Shares Gain After Releasing Early-Stage Trial Data for Kidney Cancer Treatment](https://www.marketwatch.com/story/xencor-shares-gain-after-releasing-early-stage-trial-data-for-kidney-cancer-treatment-fa350957?ref=bullished.co) — MarketWatch
- [Xencor, Inc. (XNCR) Stock Price, News, Quote & History - Yahoo Finance](https://ca.finance.yahoo.com/quote/XNCR/?ref=bullished.co) — Yahoo Finance
- [Xencor reports promising kidney cancer drug results, plans late-stage trial (XNCR:NASDAQ) | Seeking Alpha](https://seekingalpha.com/news/4657005-xencor-reports-promising-kidney-cancer-drug-results-plans-late-stage-trial?ref=bullished.co) — seekingalpha.com
- [Biggest stock movers Monday: XCNR, SGRY, AGEN | Seeking Alpha](https://seekingalpha.com/news/4657027-biggest-stock-movers-monday-xcnr-sgry-agen?ref=bullished.co) — seekingalpha.com
- [Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors – Company Announcement - FT.com](https://markets.ft.com/data/announce/detail?dockey=600-202610250435BIZWIRE%5FUSPRX%5F%5F%5F%5F20261025%5FBW921014-1&ref=bullished.co) — Financial Times